Evidence map›Paper›PMID 35894778›Full record

ArticleCancer discovery2022

A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.

Jaime Abrego, Hannah Sanford-Crane, Chet Oon, Xu Xiao, Courtney B Betts, Duanchen Sun, Shanthi Nagarajan, Luis Diaz, Holly Sandborg, Sohinee Bhattacharyya and 4 more

Abstract read
In one paragraph

Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Review
  3. GOT2-mediated suppression of CoQCommunications biology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jaime Abrego *Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-8569-2741
Hannah Sanford-Crane *Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-0049-5026
Chet OonDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-1494-6628
Xu XiaoDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-5033-7627
Courtney B BettsDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-0432-0445
Duanchen SunComputational Biology Program, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-2802-6347
Shanthi NagarajanMedicinal Chemistry Core, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-7548-0083
Luis DiazDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-7744-502X
Holly SandborgDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-1342-3136
Sohinee BhattacharyyaDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-6180-8415
Zheng XiaComputational Biology Program, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-3364-8324
Lisa M CoussensDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-2389-1865
Peter TontonozDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-1259-0477
Mara H ShermanDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-7826-3888

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5M
Omic and Multidimensional Spatial Atlas of Metastatic Breast CancerU2CCA233280 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI GOECKS, JEREMY · 2018 to 2023
$9.7M
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCCR01CA226909 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kathryn Ann Gold, Judith A VARNER · 2018 to 2026
$3.9M
Identifying and Targeting Metabolic Dependencies in the Pancreatic Tumor MicroenvironmentR01CA229580 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Mara H. Sherman · 2018 to 2026
$3.8M
Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimensU01CA224012 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRODY, JONATHAN, COUSSENS, LISA M. · 2019 to 2023
$2.9M
The Nuclear Receptor-Aster Pathway in Enterohepatic MetabolismR01DK126779 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TONTONOZ, PETER J · 2020 to 2024
$2.4M
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevicesR01CA223150 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JONAS, OLIVER · 2018 to 2022
$1.9M
Regulation of cancer cell metabolism and growth by the pancreatic tumor stromaR00CA188259 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHERMAN, MARA H. · 2017 to 2019
$747k
Mechanisms of metabolic dysfunction in the offspring of maternal obesity: role of inflammationR21HD099367 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MALOYAN, ALINA · 2019 to 2020
$411k
NCI NIH HHS P30 CA069533NCI NIH HHS R00 CA188259NCI NIH HHS R01 CA223150NCI NIH HHS R01 CA226909NCI NIH HHS R01 CA229580NCI NIH HHS U01 CA224012NCI NIH HHS U2C CA233280NICHD NIH HHS R21 HD099367NIDDK NIH HHS R01 DK126779
6 · The paper itself

Abstract

Despite significant recent advances in precision medicine, pancreatic ductal adenocarcinoma (PDAC) remains near uniformly lethal. Although immune-modulatory therapies hold promise to meaningfully improve outcomes for patients with PDAC, the development of such therapies requires an improved understanding of the immune evasion mechanisms that characterize the PDAC microenvironment. Here, we show that cancer cell-intrinsic glutamic-oxaloacetic transaminase 2 (GOT2) shapes the immune microenvironment to suppress antitumor immunity. Mechanistically, we find that GOT2 functions beyond its established role in the malate-aspartate shuttle and promotes the transcriptional activity of nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ), facilitated by direct fatty acid binding. Although GOT2 is dispensable for cancer cell proliferation in vivo, the GOT2-PPARδ axis promotes spatial restriction of both CD4+ and CD8+ T cells from the tumor microenvironment. Our results demonstrate a noncanonical function for an established mitochondrial enzyme in transcriptional regulation of immune evasion, which may be exploitable to promote a productive antitumor immune response. SIGNIFICANCE: Prior studies demonstrate the important moonlighting functions of metabolic enzymes in cancer. We find that the mitochondrial transaminase GOT2 binds directly to fatty acid ligands that regulate the nuclear receptor PPARδ, and this functional interaction critically regulates the immune microenvironment of pancreatic cancer to promote tumor progression. See related commentary by Nwosu and di Magliano, p. 2237.. This article is highlighted in the In This Issue feature, p. 2221.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPPAR deltaAspartate AminotransferasesAspartic AcidFatty AcidsHumansLigandsMalatesTumor MicroenvironmentAspartate AminotransferasesAspartic AcidFatty AcidsLigandsMalatesPPAR delta

Identifiers

PMID35894778
PMCPMC9533011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.